All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @fiitneqq on TikTok · 15s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @fiitneqq's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00It's your God, it's your God, it's your God
  2. 0:10We make this

@fiitneqq's Wegovy weight loss claims, fact-checked

fiitneqq🍑

TikTok creator

20.6K viewsWatch on TikTok

Quick answer

The creator is approximately six weeks into a Wegovy (semaglutide) weight loss regimen and reports 12 pounds of total weight loss, along with subjective improvements in appearance and wellbeing. Early weight loss of this magnitude on semaglutide is clinically plausible, particularly in the first four to six weeks when appetite suppression is often most acute and some loss reflects reduced water retention. No dosing information, contraindications, or clinical guidance is provided in the caption or the available transcript.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @fiitneqq's Wegovy weight loss claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@fiitneqq's Wegovy weight loss claims, fact-checked" from fiitneqq🍑. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is approximately six weeks into a Wegovy (semaglutide) weight loss regimen and reports 12 pounds of total weight loss, along with subjective improvements in appearance and wellbeing.

The reason this review is not generic is the source wording and the canonical claim label "glp1 i ve been on a new journey for the past month and these are." In this clip, the useful excerpt is: "It's your God, it's your God, it's your God We make this" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Early weight loss in the first four to six weeks on GLP-1 drugs is typically the steepest and often includes water weight, not just fat loss.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is approximately six weeks into a Wegovy (semaglutide) weight loss regimen and reports 12 pounds of total weight loss, along with subjective improvements in appearance and wellbeing.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is approximately six weeks into a Wegovy (semaglutide) weight loss regimen and reports 12 pounds of total weight loss, along with subjective improvements in appearance and wellbeing. Early weight loss of this magnitude on semaglutide is clinically plausible, particularly in the first four to six weeks when appetite suppression is often most acute and some loss reflects reduced water retention. No dosing information, contraindications, or clinical guidance is provided in the caption or the available transcript.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) found average weight loss of 14.9% over 68 weeks on semaglutide 2.4 mg, not in one month.
  • Early weight loss in the first four to six weeks on GLP-1 drugs is typically the steepest and often includes water weight, not just fat loss.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The STEP 1 trial (Wilding et al., 2021, NEJM) found average weight loss of 14.9% over 68 weeks on semaglutide 2.4 mg, not in one month.
  • Early weight loss in the first four to six weeks on GLP-1 drugs is typically the steepest and often includes water weight, not just fat loss.
  • Weight loss on semaglutide is not linear. Most patients experience plateaus and slowdowns, which are normal and not signs the medication has stopped working.
  • Rubino et al. (2022, JAMA) found that behavioral interventions alongside semaglutide produce significantly better outcomes than the drug alone.
  • Wegovy is a weekly subcutaneous injection. The creator's reference to a '6 week shot' almost certainly means their six-week milestone, not the injection schedule.
  • GLP-1 therapy requires a prescription and clinical supervision. Results shared on social media reflect individual experiences and are not predictive of what any other patient will experience.
  • The transcript captured only background audio, which is a reminder that many health claims in TikTok GLP-1 content travel through captions and hashtags rather than spoken words.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @fiitneqq actually say?

Honestly, the transcript here is almost nothing to work with. The audio captured is "It's your God, it's your God, it's your God We make this" — which appears to be background music or an audio overlay, not the creator speaking about their Wegovy experience. The real content lives in the caption: 12 pounds lost in roughly a month, a 6-week shot recently taken, and visible changes in face, clothing fit, and general wellbeing. So this fact-check is based on the caption claims, because the transcript didn't give us anything medically substantive to work with.

That's worth flagging on its own. A lot of GLP-1 content on TikTok carries its actual health claims in captions and hashtags rather than spoken words, which makes it harder to hold creators accountable for what they're implying.

Does the science back this up?

A 12-pound loss in roughly four to six weeks on semaglutide is plausible, but it sits at the higher end of what clinical trials typically show at this stage. It is not impossible, and it is not proof the drug is working better for this person than it does for others.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on 2.4 mg semaglutide lost an average of 14.9% of body weight over 68 weeks. Early weight loss in the first month tends to be more dramatic partly because of water weight and early appetite suppression. Davies et al. (2021, The Lancet) confirmed dose-dependent weight loss patterns, with the steepest losses often appearing in weeks one through four before plateauing. So "12 pounds down" in month one is within the range, but individual results vary significantly based on starting weight, dose titration, diet, and activity level.

The face and clothing changes the creator describes are consistent with what patients report early on, particularly facial fat redistribution, which is well-documented as a subjective early marker of loss.

What did they get wrong (or right)?

Credit where it is due: nothing in the caption makes outrageous claims. There is no promise that Wegovy will produce these results for everyone, no specific dosing advice, and no claim that the drug cures anything. That is more responsible than a lot of GLP-1 content circulating on this platform.

What is missing, and what makes this content incomplete rather than wrong, is context. Twelve pounds in a month sounds impressive in isolation. But viewers do not know this person's starting weight, their dose, whether they changed their diet, or whether this rate of loss will continue. Early semaglutide weight loss often decelerates significantly after weeks eight to twelve as the body adapts. If this creator follows up and the scale slows down, viewers primed by this video may assume something is wrong with their own treatment when it is actually normal.

The "6 week shot" framing is also a bit odd since Wegovy is a weekly injection, not a six-week one. This likely means they are at their six-week mark of the journey, not that the injection schedule is every six weeks.

What should you actually know?

GLP-1 success stories are real. The drug class has some of the strongest weight loss data in pharmaceutical history. But social media timelines compress that story in ways that can set unrealistic expectations for people just starting out.

A few things the algorithm will not tell you: semaglutide works best alongside behavioral changes (Rubino et al., 2022, JAMA). Weight loss is not linear on this drug and most people hit periods where the scale stalls. Side effects like nausea, fatigue, and gastrointestinal discomfort are common in the early titration phase and can affect how you feel before you feel better. And if you are considering Wegovy or any GLP-1 therapy, that conversation belongs with a licensed clinician who can review your full health history, not a TikTok comment section.

This video is a personal journey post, not a medical recommendation. Treat it that way.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

fiitneqq🍑 · TikTok creator

20.6K views on this video

I’ve been on a new journey for the past month and these are my results so far .. 12 pounds down as of yesterday, I took my 6 week shot yesterday as well! I can definitely see a difference in my face a

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial (wilding et al., 2021, nejm) found?

The STEP 1 trial (Wilding et al., 2021, NEJM) found average weight loss of 14.9% over 68 weeks on semaglutide 2.4 mg, not in one month.

What does the video say about early weight loss in the first four to six weeks?

Early weight loss in the first four to six weeks on GLP-1 drugs is typically the steepest and often includes water weight, not just fat loss.

What does the video say about weight loss on semaglutide?

Weight loss on semaglutide is not linear. Most patients experience plateaus and slowdowns, which are normal and not signs the medication has stopped working.

What does the video say about rubino et al. (2022, jama) found?

Rubino et al. (2022, JAMA) found that behavioral interventions alongside semaglutide produce significantly better outcomes than the drug alone.

What does the video say about wegovy?

Wegovy is a weekly subcutaneous injection. The creator's reference to a '6 week shot' almost certainly means their six-week milestone, not the injection schedule.

What does the video say about glp-1 therapy requires a prescription?

GLP-1 therapy requires a prescription and clinical supervision. Results shared on social media reflect individual experiences and are not predictive of what any other patient will experience.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by fiitneqq🍑, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.